SPR and Nephroblastoma: The identified prognostic genes, particularly GRAMD1A, SPR, EBAG9, RBM47, and RIDA, offer significant potential as both prognostic biomarkers and therapeutic targets for improving personalized treatment in Wilms tumor patients.